Inhibiting activin-A signaling stimulates bone formation and prevents cancer-induced bone destruction in vivo (Q39695455)

14 September 2017

Inhibiting activin-A signaling stimulates bone formation and prevents cancer-induced bone destruction in vivo (English)

1 reference

14 September 2017

10

Mary L Bouxsein

1 reference

14 September 2017

Andrew D Chantry

1

1 reference

14 September 2017

Debby Heath

2

1 reference

14 September 2017

Aaron W Mulivor

3

1 reference

14 September 2017

Scott Pearsall

4

1 reference

14 September 2017

Marc Baud'huin

5

1 reference

14 September 2017

Les Coulton

6

1 reference

14 September 2017

Holly Evans

7

1 reference

14 September 2017

Nicole Abdul

8

1 reference

14 September 2017

Eric D Werner

9

1 reference

14 September 2017

Michelle L Key

11

1 reference

14 September 2017

Jasbir Seehra

12

1 reference

14 September 2017

Timothy R Arnett

13

1 reference

14 September 2017

Karin Vanderkerken

14

1 reference

14 September 2017

Peter Croucher

15

1 reference

14 September 2017

7 June 2010

1 reference

Journal of Bone and Mineral Research

14 September 2017

1 reference

14 September 2017

25

1 reference

14 September 2017

2633-2646

1 reference

14 September 2017

12

1 reference

Metastasis to bone: causes, consequences and therapeutic opportunities

14 September 2017

1 reference

Metastatic bone disease: clinical features, pathophysiology and treatment strategies

21 January 2018

1 reference

Evidence for the secretion of an osteoclast stimulating factor in myeloma.

21 January 2018

1 reference

Recruitment of new osteoblasts and osteoclasts is the earliest critical event in the pathogenesis of human multiple myeloma

21 January 2018

1 reference

Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases

21 January 2018

1 reference

Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial

21 January 2018

1 reference

Pituitary FSH is released by a heterodimer of the beta-subunits from the two forms of inhibin.

21 January 2018

1 reference

Purification and characterization of an FSH releasing protein from porcine ovarian follicular fluid

21 January 2018

1 reference

Evidence for ovarian “inhibin”: Suppression of the secondary rise in serum follicle stimulating hormone levels in proestrous rats by injection of porcine follicular fluid

21 January 2018

1 reference

Inhibin, activin and the female reproductive axis

21 January 2018

1 reference

The tissue distribution of activin beta A- and beta B-subunit and follistatin messenger ribonucleic acids suggests multiple sites of action for the activin-follistatin system during human development

21 January 2018

1 reference

MEKK1 transduces activin signals in keratinocytes to induce actin stress fiber formation and migration

21 January 2018

1 reference

Overexpression of activin A in the skin of transgenic mice reveals new activities of activin in epidermal morphogenesis, dermal fibrosis and wound repair

21 January 2018

1 reference

The activin A-follistatin system: potent regulator of human extracellular matrix mineralization

21 January 2018

1 reference

Activin A is an essential cofactor for osteoclast induction.

21 January 2018

1 reference

A soluble activin type IIA receptor induces bone formation and improves skeletal integrity

21 January 2018

1 reference

Activin A circulating levels in patients with bone metastasis from breast or prostate cancer.

21 January 2018

1 reference

Hypoxia is a major stimulator of osteoclast formation and bone resorption.

21 January 2018

1 reference

21 January 2018

1 reference

Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee

21 January 2018

1 reference

Multiple myeloma biology: lessons from the 5TMM models

21 January 2018

1 reference

Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease

21 January 2018

1 reference

A soluble activin receptor Type IIA fusion protein (ACE-011) increases bone mass via a dual anabolic-antiresorptive effect in Cynomolgus monkeys

21 January 2018

1 reference

Follistatin suppresses the production of experimental multiple-organ metastasis by small cell lung cancer cells in natural killer cell-depleted SCID mice

21 January 2018

1 reference

Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival.

21 January 2018

1 reference

Antitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasis.

21 January 2018

1 reference

Role of decorin in the antimyeloma effects of osteoblasts

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/JBMR.142

1 reference

14 September 2017

1 reference